Atopic dermatitis is a chronic inflammatory skin condition with a relapsing–remitting course that varies in morphology and has features of xerosis, pruritus, and subsequent lichenification from repetitive scratching. Facial erythema and extensor involvement is the usual distribution of spongiotic dermatitis in infants and children, whereas adults usually experience flexural lichenification. Atopic dermatitis is often associated with a personal or family history of atopy (such as allergic rhinitis, atopic dermatitis, and asthma) and may be associated with immunoglobulin E (IgE) reactivity [1–5]. In European countries, the lifetime prevalence of atopic dermatitis in school-aged children is estimated to be between 10% and 20% [4]. Data from Laughter et al. in 2000 indicate that the prevalence of atopic dermatitis in the northwest US is similar to that in European countries and in Japan [6]. Developed countries, urban areas, and populations of high socioeconomic status experience a high prevalence of atopic dermatitis, for reasons that are unclear [1,6]. Pediatric patients with atopic dermatitis require frequent trips to healthcare providers and incur significant costs associated with pharmacological treatment and office visits. In the US, between 1997 and 2004, pediatric patients (aged 0–18 years) with atopic dermatitis made an estimated 7.4 million office visits for consultation and treatment [5]. Other than healthcare expenses [7], atopic dermatitis has consequences on quality of life issues that involve both the patient and their family [1]. Spontaneous remission can occur in children with atopic dermatitis. Approximately 60% of childhood cases are disease- or symptom-free by early adolescence. Early-onset disease, a family or personal history of atopy, and disease severity are factors that indicate more persistent atopic dermatitis [8].